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Simple Summary: Acute myeloid leukemia (AML) is a hematological neoplasm with a very poor
survival rate. To date, diagnostic tools to monitor individuals at higher risk of developing AML
are scarce. Single nucleotide polymorphisms (SNPs) have emerged as good candidates for disease
prevention. AML is characterized by altered autophagy, a vital mechanism to remove and recycle
unnecessary or dysfunctional cellular components. ATG10 is one of the autophagy core genes
involved in the autophagosome formation. We hypothesize that SNPs located in regulatory regions
of the ATG10 gene could predispose individuals to AML development. We therefore genotyped
three SNPs within the ATG10 locus. We identified the ATG10rs3734114 as a potential risk factor for
developing AML, whereas the ATG10rs1864182 was associated with decreased risk. These findings
highlight ATG10 as a key regulator of susceptibility to AML. Furthermore, we believe that ATG10
SNPs could be exploited in the clinical setting as an AML prevention strategy.
Abstract: Acute myeloid leukemia (AML) is the most common acute leukemia, characterized by a
heterogeneous genetic landscape contributing, among others, to the occurrence of metabolic repro-
gramming. Autophagy, a key player on metabolism, plays an essential role in AML. Here, we exam-
ined the association of three potentially functional genetic polymorphisms in the ATG10 gene, central
for the autophagosome formation. We screened a multicenter cohort involving 309 AML patients and
356 healthy subjects for three ATG10 SNPs: rs1864182T>G, rs1864183C>T and rs3734114T>C. The
functional consequences of the ATG10 SNPs in its canonical function were investigated in vitro using
peripheral blood mononuclear cells from a cohort of 46 healthy individuals. Logistic regression anal-
ysis adjusted for age and gender revealed that patients carrying the ATG10rs1864182G allele showed a
significantly decreased risk of developing AML (OR [odds ratio] = 0.58, p = 0.001), whereas patients
carrying the homozygous ATG10rs3734114C allele had a significantly increased risk of developing AML
(OR = 2.70, p = 0.004). Functional analysis showed that individuals carrying the ATG10rs1864182G allele
had decreased autophagy when compared to homozygous major allele carriers. Our results uncover
the potential of screening for ATG10 genetic variants in AML prevention strategies, in particular for
subjects carrying other AML risk factors such as elderly individuals with clonal hematopoiesis of
indeterminate potential.
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1. Introduction
Acute myeloid leukemia (AML) is the most common acute leukemia in adults with
an average age of disease diagnosis above 65 years old [1]. It is a highly heterogeneous
clonal disorder characterized by an impairment in myeloid cellular differentiation and
deregulated proliferation, leading to an accumulation of immature myeloid progenitor
cells in the bone marrow (BM), peripheral blood, and other tissues. Patients undergoing
chemotherapy, radiation, or with a genetic predisposition to myeloid neoplasms are at a
higher risk of developing AML [2]. Furthermore, it has been reported that individuals
presenting an age-related condition named clonal hematopoiesis of indeterminate potential
(CHIP), are also at higher risk of developing AML. CHIP is characterized by the expansion
of hematopoietic stem cell (HSC) clones, harboring specific, disruptive, and recurrent
somatic mutations [3]. Thus, searching for markers of AML predisposition and progression
is of important clinical relevance.
Single nucleotide polymorphisms (SNPs) have emerged as new predictors of dis-
eases like cancer and as indicators of effectiveness of chemotherapy response. To date,
the majority of SNPs reported in association with AML are focused on the response to
oncological therapies [4–7]. For example, the STAT3rs9909659 could be used to predict the
treatment outcome to chemotherapy with daunorubicin and cytarabine [8]. Moreover, a
SNP located in the mutational hotspot of Wilms tumor 1 (WT1) was identified as a novel
favorable prognostic marker in cytogenetically normal AML [9]. The SNP rs11554137
present at the isocitrate dehydrogenase 1 (IDH1) gene, a citric acid cycle enzyme involved
in metabolism, was shown to be a negative outcome predictor of AML [10,11]. The presence
of IDH1rs11554137 results in the production of the oncometabolite (R)-2-hydroxyglutarate
leading to the poor prognosis of normal karyotype adult AML. This particular finding
may indicate the potential presence of other SNPs involved in the complex pathways of
metabolism and perhaps in cellular recycling mechanisms such as autophagy. Interestingly,
AML is characterized by changes in autophagy flux in both pre-leukemic cells as well as
in leukemic stem cells, as a consequence of acquired somatic mutations, a process asso-
ciated with increased age [12]. Despite these advances, the need for finding novel SNPs
associated with AML predisposition remains. Only few SNPs have been associated with
higher risk of developing myeloid leukemia [13]. As an example, the presence of the B-cell
lymphoma 2 (BCL2) polymorphism, BCL2938C/A and the BCL2-associated X protein (BAX)
polymorphism, BAX248GG were significantly associated with an increased risk of AML
occurrence [14]. Furthermore, two SNPs in CASP9 gene (rs1263 and rs712) are associated
with AML susceptibility [15].
Autophagy is a coordinated process responsible for the removal of misfolded proteins
and dysfunctional organelles from cells by means of lysosomal degradation [16]. Au-
tophagy plays a key role in cancer since it can either suppress tumorigenesis by inhibiting
cancer cell survival, or facilitate tumorigenesis by promoting cancer cell proliferation and
tumor growth [17,18]. Recent studies have shown autophagy-related prognostic signature
for AML prediction [19]. An important step in autophagy is the autophagosome formation,
which is mediated by a set of ATG proteins such as ATG10. ATG10 is an E2-like enzyme that
catalyzes the conjugation reaction between ATG12 and ATG5, when interacting with ATG7,
an essential set for autophagy vesicle formation [20]. Interestingly, apart from ATG10’s role
in autophagy, ATG10 seems to have a non-canonical function in inflammation [21,22].
The Human Genome Project has identified many ATG10 SNPs, but to date only few
were investigated in AML research [23]. The two missense ATG10rs1864182 and ATG10rs1864183
were shown to be situated in the region containing enhancer histone markers in induced
pluripotent stem cells (iPSCs), and they are possible motifs altering binding of the tran-
scription factors DMRT1 and Myc [24]. Curiously, DMRT1 and Myc are key players in
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the development of AML [25,26]. Another missense ATG10 SNP, the ATG10rs3734114, was
described for its putative involvement in lung, thyroid, brain and bladder cancers [27–30].
For these reasons, in this work we studied the association of AML development with these
three ATG10 SNPs (ATG10rs1864182, ATG10rs1864183 and ATG10rs3734114), using a Spanish
cohort of AML patients and healthy donors, with a total of 665 participants. We further
evaluated the autophagic function of the associated SNPs using an independent cohort of
46 healthy donors. Our results demonstrate the importance of autophagy-related ATG10
SNPs in AML development.
2. Materials and Methods
2.1. Ethics Statement
Two independent cohorts were used for this study. Cohort 1 consisted of 665 Spanish
subjects, including 309 AML subjects and 356 healthy subjects that were ascertained through
the NuCLEAR consortium [31]. All ethical issues concerning this cohort are described
in [31]. Cohort 2 included 46 healthy Portuguese subjects. The study was approved by
the Ethics Committee for Research in Life and Health Sciences (CEICVS) at University of
Minho (SECVS 010/2015).
2.2. DNA Extraction, SNP Selection Criteria and Genotyping
Genomic DNA from whole blood samples was isolated using the NZY Blood gDNA
Isolation kit (NZYTech, Lisbon, Portugal) according to the manufacturer’s instructions.
The frequency of each selected SNP in the Caucasian population was considered, based on
the International HapMap Project (HapMap-CEU). Genotyping of the ATG10rs1864182 and
ATG10rs1864183 was performed using the KASPar genotyping chemistry (LGC Genomics,
Hoddesdon, UK) and ATG10rs3734114 using TaqMan SNP Genotyping Assay (Thermo Fisher
Scientific, MA, USA), following the manufacturer’s instructions. Call rate for all tested
SNPs was >98%. Quality control for the genotyping results were achieved with negative
controls and randomly selected samples included as duplicates.
2.3. Association Studies
For both cohorts, contingency tables were calculated. Association studies were per-
formed following the methods described in [32] using Rstudio version 1.4.1103. The major
allele was considered the most frequent allele in the European population based on Na-
tional Library of Medicine (NIH). Hardy–Weinberg Equilibrium (HWE) and corresponding
significant differences were calculated for the control population of each SNP using a
standard observed-expected chi-square (χ2) test. The genotypic odds ratios (OR) for the
dominant and recessive model as well as the corresponding confidence intervals were
calculated, and both χ2 and Fischer exact (FE) test were performed. Logistic regression for
the dominant and recessive model adjusted for age and gender was performed to control
for these possible confounding factors. Since we simultaneously assessed other autophagy
SNPs in this study, we performed a correction for multiple testing using the Bonferroni
method (Supplementary Table S1). Linkage Disequilibrium (LD) between the three studied
ATG10 SNPs studied was analyzed using Haploview software.
2.4. mRNA Expression Analysis by qRT-PCR
Analysis of quantitative mRNA expression was accomplished according to MIQE
guidelines [33]. In brief, ATG10 mRNA transcripts expression levels were measured by
quantitative real-time PCR (qPCR) (Supplementary Table S2). The expression levels of
these transcripts were normalized against that of three reference genes: β-2-microglobulin
(B2M), ribosomal protein L13a (RPL13A), Glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) (Supplementary Table S2).
The RNA extraction was performed using the NZYol RNA Isolation Reagent (NZYTech).
Total RNA (250 ng) was reverse-transcribed into cDNA in a 20 µL reaction mixture using
the NZY First-Strand cDNA Synthesis kit (NZYTech). Then, in a 20 µL reaction mixture,
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50 ng of cDNA, of each sample, were tested in duplicate in a 96-well plate (Bio-Rad, CA,
USA). The qPCR was processed in a CFX96™ Real Time System (Bio-Rad), with the NZY
qPCR Green Master Mix (NZYTech), according to the manufacturer’s instructions. A blank
(no-template control) was also included in each assay run. The qPCR conditions consisted
of one hold at 95 ◦C for 1 min, followed by 45 cycles of 15 min at 95 ◦C, 20 s at 60 ◦C and
20 s at 72 ◦C. At the end, a melting-curve was acquired to evaluate the PCR specificity,
contamination and the absence of primer dimers. Furthermore, the PCR efficiency was also
tested according to methods described in [33]. Final values of relative expression levels of
ATG10 mRNA transcripts were determined by correcting for the differences in efficiencies
between target and reference genes using the gene expression software of the CFX manager
program (Bio-Rad).
2.5. Protein Expression and Immunoblot Analysis
For protein extraction, 50 µL of lysis buffer was used, containing 1% NP-40, 500 mM Tris
HCL, 2.5 M NaCl, 20 mM EDTA, Phosphatase and Protease inhibitors (Roche, Mannheim,
Germany), at pH 7.2, followed by a sonication process. For the immunoblotting assay, 20 µg
of total protein extract were resolved in a 12% SDS gel and transferred to a nitrocellulose
membrane during 10 min, using the Trans-Blot Turbo transfer system (Bio-Rad). Then,
membranes were blocked using Tris-buffered saline (TBS) with 0.1% tween 20 (TBS-T)
plus 5% bovine serum albumin (BSA) and incubated overnight at 4 ◦C. This incubation
was performed with the polyclonal primary antibodies resuspended in 1% BSA: Rabbit
anti-LC3A/B Antibody (1:1000, Cell-Signaling, MA, USA), mouse anti-p62 (1:1000, Abcam,
Cambridge, UK), anti-mono and polyubiquitination conjugated (1:1000, Enzo Biochem,
NY, USA ) or mouse anti-alpha-actin (1:1000, Millipore, MA, USA), followed by one hour
incubation with the secondary antibodies (HRP, anti-rabbit, anti-mouse 1:5000) (Bio-Rad).
Blots were developed with the SuperSignal West Femto Maximum Sensitivity Substrate
(Thermo Fisher Scientific) or the Clarity Western ECL Substrate (Bio-Rad). Digital images
were obtained in a ChemiDoc XRS System (Bio-Rad) and the densitometry analysis of the
bands was performed with the Quantity One software V4.6.5 (Bio-Rad).
2.6. Peripheral Blood Mononuclear Cells (PBMC) Isolation
Venous blood was drawn into 10 mL EDTA tubes. Blood was diluted in PBS (1:1) and
fractions were separated by Histopaque®-1077 (Sigma-Aldrich, MO, USA) density gradient
centrifugation according to the protocol of the manufacturer. PBMCs were washed twice
with PBS and resuspended in RPMI-1640 medium (Gibco, Paisley, UK) supplemented 10%
FBS (Gibco) and antibiotic-antimycotic solution (Sigma-Aldrich).
2.7. Autophagy Flux Analysis
Briefly, PBMCs were plated in 12-well round-bottom plates (Corning, NY, USA) at
a concentration of 5 × 105 cell/mL and incubated, with or without 10 µM of metformin
(Sigma-Aldrich), for 4 h. Furthermore, in order to block the autophagy flux and to allow the
accumulation of LC3-II [34], 2 h before the end of the treatment, in each condition, cells were
also incubated with 10 nM of bafilomycin (Baf A1) (Sigma-Aldrich). After incubation, cells
were lysed and immunoblotting assays were performed for autophagy-related proteins, as
described in 2.5. To quantify autophagy synthesis, the ratio of the values of the cells treated
with metformin and Baf A1 against those for condition without metformin but with Baf
A1 treatment was determined. To quantify autophagy degradation, the ratio between the
densitometric values of cells treated with metformin in the presence or absence of Baf A1
was determined, according to autophagy standard guidelines [34]. Due to the number of
samples in our study and the limited amount of protein per sample, technical replicates
of the blots were not performed, however most conditions contain enough samples to
warrant a reliable statistical analysis, with exception of samples for ATG10rs3734114C/C for
which statistical tests were not performed.
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2.8. Statistical Analysis
Each condition was tested for normality before statistical analysis using a Shapiro-Wilk
test. To compare one or two normally distributed samples a t-test was performed. For more
than two samples an ANOVA test was performed. When at least one of the samples was
non-normally distributed, the Kruskal–Wallis test was performed. All statistical procedures
were conducted using GraphPad Prism.
3. Results
3.1. Demographic Characterization of the Cohorts
Two European cohorts were used, one for SNP analysis (cohort 1) and the other for
functional studies (cohort 2). Demographic characterization of the cohorts is detailed in
Table 1. Cohort 1 consisted of 665 Spanish subjects from the NuCLEAR consortium [31]
comprising 309 AML patients and 356 healthy subjects. Gender balance was observed
in cohort 1 (χ2 test, p = 0.612), while age distribution was statistically different between
AML cases and healthy controls (56 ± 6 and 58 ± 17 years mean age, respectively, p < 0.05).
The association analyses were adjusted for age and gender. Cohort 2, which included 46
healthy subjects, was used for functional studies (Table 1).






Age 56 ± 6 years mean age









Age 39 ± 14 years mean age
NA denotes non-available.
3.2. Linkage Analysis of ATG10 SNPs
The ATG10 polymorphisms studied are located on the chromosome 5, at the positions
82253421, 82253397 and 82058570 for the ATG10rs1864182, ATG10rs1864183 and ATG10rs3734114,
respectively (Table 2, Supplementary Figure S1A). Random association of the SNPs al-
leles in the ATG10 locus was analyzed by calculating the allelic linkage (Supplemen-
tary Figure S1B). Linkage disequilibrium (LD) analysis showed a close association of
ATG10rs1864182 with ATG10rs1864183 (coefficient of LD (D’) of 0.93 and r2 of 0.62). A mod-
erate linkage between these two SNPs was expected due to their loci proximity. For the
linkage between ATG10rs3734114 and ATG10rs1864183 or ATG10rs1864182, D’ and r2 values
were low, ranging from 0.17–0.26 and 0.0–0.02 respectively, showing that the ATG10rs3734114
represents an independent signal.
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Table 2. Information regarding the ATG10 polymorphisms. Major allele was considered the most
frequent allele in the European population based on the National Library of Medicine for the
corresponding SNP.
Genotyped SNPs rs1864182 rs1864183 rs3734114
Chromosome 5 5 5
Chromosome Position 82253421 82253397 82058570
Major Allele T C T
Base change T > G C > T T > C
Minor Allele Frequency (MAF) in the controls 0.508 0.429 0.202
p value for HWE test in our controls 0.821 0.302 0.365
3.3. Associations of Genetic Variants on ATG10 with AML
Associations of ATG10rs1864182, ATG10rs1864183 and ATG10rs3734114 with AML were
studied in cohort 1. Minor allele frequencies in the control population, as well as the
nucleotide changes for each SNP are presented in Table 2 and Supplementary Figure S1A,
respectively. All SNPs were in Hardy–Weinberg equilibrium (HWE) (Table 2).
Allele and genotype frequencies were in line with those reported by the NIH for
the CEU population (https://www.ncbi.nlm.nih.gov/snp/, accessed 12 January 2021)
(Tables 2 and 3). The genotype distributions for the ATG10rs3734114 were different be-
tween patients and controls (χ2 test, padjusted = 0.012, respectively) (Table 3). Logistic
regression analysis adjusted for age and gender revealed that AML patients carrying the
ATG10rs1864182G allele showed a significant decreased risk of developing AML (ORDominant =
0.58, with a 95% confidence interval [CI] = 0.42–0.80, Table 3), whereas patients carrying the
ATG10rs3734114C/C genotype had a significant increased risk of developing AML when com-
pared with those carrying the most common allele (ORRecessive = 2.70, 95% CI = 1.36–5.34,
Table 3). All results were corrected for multiple testing using Bonferroni correction (Sup-
plementary Table S1). Our analysis confirmed that older subjects [35,36] and males [37] are
at higher risk of developing AML. In summary, our results proposed a decreased risk of
developing AML when carrying the ATG10rs1864182G, whereas identified ATG10rs3734114C/C
as a risk factor for the development of AML.
Table 3. Association of ATG10 SNPs with Acute Myeloid Leukemia (AML). Adjusted odds ratio (OR) and 95% confidence
intervals (CIs) for association between SNPs and AML were estimated using logistic regression.
SNPs Genotypes






Control AML OR (CI) OR (CI)
rs1864182




p = 0.001; pad = 0.006
0.70
(0.47–1.04)
p = 0.077; pad = 0.462
TG 154 (49) 110 (44)
GG 81 (26) 53 (21)
rs1864183




p = 0.113; pad = 0.678
1.31
(0.88–1.94)
p = 0.180; pad = 1.080
CT 146 (46) 126 (47)
TT 63 (20) 65 (24)
rs3734114




p = 0.414; pad = 2.484
2.70
(1.36–5.34)
p = 0.004; pad = 0.024
TC 92 (30) 53 (21)
CC 14 (4) 28 (11)
Abbreviations: Logistic Regression (LR), Fisher Exact Test (FE), Chi-Square test (χ2), p value (p), adjusted p value using Bonferroni method
for multiple testing (pad).
3.4. Impact of ATG10rs1864182 and ATG10rs3734114 in mRNA and Protein Levels
The impact of ATG10 SNPs associated with AML on mRNA expression and on the
protein levels of ATG10 isoforms was assessed in PBMCs of healthy donors from cohort
2. The genotype characterization of ATG10 SNPs in cohort 2 is presented in Table 4.
The similarity in genotype frequencies between cohort 2 and the CEU population (https:
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//www.ncbi.nlm.nih.gov/snp/, accessed 12 January 2021) supported the use of this cohort.
For the ATG10rs1864182, we followed the predicted dominant model as indicated by our
analysis (Table 3) and therefore, TG and GG genotypes were combined in one group.
Regarding ATG10rs3734114, the predictive model suggested a recessive behavior of the
alternative C allele and therefore both TT and TC genotypes were combined. However,
due to the low frequency of CC (4.3% in cohort 2), statistical analysis was not conducted
for this SNP.
Table 4. Genotype frequencies for the ATG10rs1864182 and ATG10rs3734114 in cohort 2.









As mentioned earlier, ATG10 is an E2-like enzyme involved in E2 ubiquitin-like
modifications, crucial for autophagosome formation [38]. Previous studies showed the
existence of at least three different ATG10 protein isoforms, Q9H0Y0 (the longest isoform)
and variants X3 and D6RDX3 (shorter isoforms) (Figure 1A) [22]. Q9H0Y0 is composed
of 663 nucleotides, encoding 220 amino acids, whereas the isoform Variant X3 has 555
nucleotides coding for 184 amino acids (from www.ncbi.nlm.nih.gov/CCDS/, accessed
12 January 2021). Both short isoforms present identical sequences with the exception of a
deletion of 36 amino acids in the N-terminal of Variant X3 [21,22]. The D6RDX3 isoform
also has 555 nucleotides coding for 184 amino acids, but the 36 amino acids deletion occur
at the C-terminal region. As a result of these deletions, isoforms Variant X3 and D6RDX3
have the same molecular weight of 21 kDa, whereas the long isoform has a molecular
weight of 25 kDa.
Despite the ATG10 isoforms described, the study of the ATG10 mRNA levels was
performed using a set of primers allowing for the amplification of a region common to
all isoforms (Supplementary Table S2). The results demonstrated that the presence of the
ATG10rs1864182 did not have any significant impact on ATG10 mRNA levels (Figure 1B).
With regards to the presence of ATG10rs3734114, the two recessive individuals for the alter-
native allele C had a higher mRNA expression than heterozygous individuals, although
the significance of this trend could not be verified by statistical analysis (Figure 1C).
The selected ATG10 antibody allowed distinguishing the longest from the shorter
isoforms (Figure 1D). Immunoblot analysis revealed that none of the ATG10 isoforms
are predominantly associated with a particular ATG10rs1864182 genotype (Figure 1E). No
conclusions could be drawn for ATG10rs3734114, but it is nonetheless interesting to note
that the two individuals carrying the homozygous alternative allele C only displayed the
longest ATG10 isoform (Figure 1F).
We next evaluated the protein levels of the ATG10 long isoform, which is mainly
involved in autophagy catalytic function [21,22]. In the presence of the ATG10rs1864182G,
a statistically significant decrease of 25% in the ATG10 long isoform levels was observed
(Figure 1G). It is interesting to note that both healthy donors with homozygous high-risk
ATG10rs3734114 genotype showed a higher mean value of ATG10 long isoform levels than
when in the presence of major allele (Figure 1H). These results are in accordance with
the higher mRNA expression levels observed (Figure 1C). Based on these results, we
further evaluated the functional impact of these ATG10 SNPs on ATG10 canonical function
in autophagy.
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Figure 1. (A) Schematic representation of ATG10 protein sequence and the corresponding long
(Q9H0Y0, black) and short (Variant X3 and D6RDX3, orange and green, respectively) isoforms.
(B,C) ATG10 mRNA levels of individuals carrying ATG10rs1864182 and ATG10rs374114, respectively.
(D) Illustrative western blot analysis of ATG10 isoforms: long (25kDa, sample 45) and short (21kDa,
sample 46). (E,F) Genotype frequencies of short and long ATG10 isoforms in the dominant model
for rs1864182 and recessive model for rs374114, respectively. Black squares represent the percentage
of individuals with the presence of the long isoform, whereas white squares correspond to the
percentage of individuals with long and short isoforms. (G) Levels of ATG10 long isoform for the
ATG10rs1864182 carriers (* denotes p < 0.05, unpaired t-test). (H) ATG10 long isoform levels for the
ATG10rs3734114 carriers. Protein levels were normalized by β-actin level. Error bars denote one
standard deviation.
Cancers 2021, 13, 1344 9 of 15
3.5. Functional Effects of ATG10rs1864182 and ATG10rs3734114 on Autophagy
To investigate whether autophagy is affected by the presence of the protective or risk
in ATG10 SNPs identified in our association analysis, we evaluated autophagic flux in
PBMCs from healthy donors. Measurements were performed in both basal and stimulated
conditions. For the latter, cells were treated with the autophagy inducer metformin during
4 h [39]. Autophagy flux was assessed by LC3 processing performed according to gold stan-
dard guidelines [34]. During autophagy, LC3-I is conjugated to phosphatidylethanolamine
(PE) to form LC3-II, which co-localizes at the autophagosome membranes thus reflect-
ing the number of autophagosomes and autophagy-related structures. When analyzing
LC3-II levels in PBMCs of healthy donors (Figure 2A) carrying either ATG10rs1864182 or
ATG10rs3734114, no significant differences were found in both basal and stimulated condi-
tions between genotypes (Figure 2B,C). LC3-II has a high recycling turnover, synthesis and
degradation. Therefore, we used an autophagosome-lysosome fusion inhibitor, bafilomycin
A1 (Baf A1), to block this process, allowing the accumulation of autophagosomes. Under
normal autophagic flux an accumulation of LC3-II is expected, and alterations in LC3-II
accumulation suggest an imbalance by defaulted synthesis and/or degradation. LC3-II
synthesis was assessed by computing the ratio of the LC3-II protein levels from stimulated
conditions (treated with metformin) plus Baf A1 over the LC3-II protein levels of the sam-
ples under basal conditions with Baf A1 alone. The LC3-II degradation was also assessed
by computing the ratio of the LC3-II protein levels in stimulated conditions plus Baf A1
over the LC3-II protein levels obtained under stimulated conditions only (Figure 2A) [34].
For the ATG10rs1864182, LC3-II synthesis was not significantly affected by the presence
of the alternative allele (Figure 2D). On the other hand, the LC3-II degradation was reduced
in individuals with this SNP, although this trend did not achieve statistical significance
(Figure 2E). These observations suggested that the ATG10rs1864182G may be associated
with a decreased autophagy flux. No differences were observed when evaluating LC3-II
synthesis and degradation in individuals with and without the ATG10rs374114C/C. However,
note the sample size of n = 2 in this case (Figure 2F,G).
p62 is a multifunctional protein involved in different pathways, including autophagy
and the proteasomal degradation of ubiquitinated proteins. p62 is an autophagy substrate
and like LC3-II has been extensively used as a reporter of autophagy activity [40]. Al-
terations in p62 accumulation and degradation also suggest changes in autophagic flux.
Indeed, LC3 co-localizes and is immunoprecipitated with p62, suggesting that these two
proteins are involved in the same complexes [41]. Furthermore, it is described that the
turnover of p62 occurs in the same conditions as LC3 [41]. Altogether, autophagy inhibition
leads to an increase of p62 protein levels. We next examined the accumulation and the
degradation of p62 (Figure 2H). The total p62 levels for both of the studied SNPs did not
reveal significant differences when comparing individuals with the presence of minor
alleles (Figure 2I,J). However, when analyzing p62 accumulation and degradation, as done
for LC3-II [41], in the presence of ATG10rs1864182G, we found a significant increase in the
p62 accumulation (Figure 2K), without major alterations on p62 degradation (Figure 2L).
Decrease of LC3-II degradation and an increase of p62 accumulation is associated with a
reduction of autophagy flux [34]. No differences in p62 were observed between the two
groups with ATG10rs374114C/C (Figure 2M,N, note n = 2).
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Figure 2. (A) Representative blot for study of LC3 processing. For ATG10rs1864182 and ATG10rs3734114: (B,C) LC3-II levels;
(D,F) LC3 synthesis and (E,G) degradation. (H) Representative blot for p62 levels. For ATG10rs1864182 and ATG10rs3734114:
(I,J) p62 levels; (K,M) p62 accumulation and (L,N) degradation. (O) Representative blot for ubiquitination profile and
(P,Q) graphical representation of the intensity of total UB/β-actin obtained by densitometric analysis, for ATG10rs1864182
and ATG10rs3734114, respectively. Statistical significance of the data was determined by Mann Whitney test (* p ≤ 0.05). The
error bars represent one standard error of the mean (SEM).
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Impaired autophagy leads to an accumulation of ubiquitinated proteins [42], which
could be associated with a faulty degradative process such as the ubiquitin proteasome
system (UPS). Ubiquitination is a well-known post-translational modification, involving
the conjugation of different ubiquitin length chains to proteins [43]. Depending on the
distinct structure of the ubiquitin chains, the protein outcome will be different (degradation,
signal transduction or subcellular localization) [44]. Thus, to further support the defective
autophagy observed in individuals presenting the ATG10rs1864182G and to evaluate its
impact on the proteasomal degradation, we evaluated the total ubiquitination profile
by immunoblot analysis (Figure 2O). Our results revealed that individuals carrying the
ATG10rs1864182G tended to present increased levels of ubiquitinated proteins (Figure 2P).
Regarding the ATG10rs374114C/C no major conclusions could be drawn (Figure 2Q).
In summary, concerning the ATG10rs1864182, the results herein suggest a diminished
autophagic flux in individuals with the protective G allele, resulting from decreased LC3-II
degradation and consequent p62 accumulation. This also suggests that individuals who
do not display the protective allele exhibit higher autophagy activity. Furthermore, these
changes in autophagy appear to have a mild impact on the UPS system, since individuals
presenting the ATG10rs1864182G appear to have increased levels of ubiquitinated proteins.
For the ATG10rs374114, no major conclusions could be drawn, due to the low frequency of
the risk homozygous allele in the population.
4. Discussion
AML is a severe disease with a rapid progression and a high fatality rate, particu-
larly in the elderly. AML affects 3 to 4 persons per 100,000 per year (https://seer.cancer.
gov/statfacts/html/amyl.html, accessed 12 January 2021). The existence of a familiar
or personal medical history (e.g., close relatives with AML, blood disorders, and genetic
syndromes), the incidence of a primary cancer undergoing chemotherapy, and the presence
of clonal hematopoiesis of indeterminate potential (CHIP) are well-known risk factors for
AML development. Therefore, the development of new strategies for risk stratification of
individuals at higher risk will be important to place them on the medical radar.
After studying the impact of different SNPs on autophagy and other-related processes
(Supplementary Table S1), in this study, we evaluated the association between three SNPs
in the ATG10 gene with AML in a case-control study. SNPs have been recognized as
risk factors for disease development and are an excellent tool to investigate etiology,
inter-individual differences in treatment response, and outcomes of cancers [45]. Genetic
variations of autophagy core genes have been the focus of research in several human
cancers [46]. The ATG10rs1864182 has been previously associated with decreased risk of
breast cancer [47] and melanoma [48]. However, other studies have shown the association
of the ATG10rs1864182 with poor lung cancer survival in particular on the non-small cell lung
cancer (NSCLC) [24]. To the best of our knowledge, our study is the first to examine the
association of ATG10 SNPs with AML and to explore the functional implications of these
SNPs on autophagy. We described the association of ATG10rs1864182G with a decreased
probability of developing AML. ATG10rs1864182 was also shown to serve as biomarker
for primary or acquired resistance to chemotherapy when using gefitinib (an epidermal
growth factor receptor (EGFR)-TKI drug) in advanced lung adenocarcinoma patients with
EGFR mutations [49]. Studying the involvement of ATG10rs1864182 in the resistance to
chemotherapy may be a useful future biomarker for tailoring AML treatments.
ATG10rs3734114 was recently associated with increased brain metastasis in NSCLC
patients [30]. The study showed that patients carrying the ATG10rs3734114CT/CC geno-
types had an increased cumulative brain metastasis hazard of 46% compared to 13% in
patients with the TT genotype [30]. In our studies, we found for the first time an associa-
tion of the ATG10rs3734114C/C with a higher risk of developing AML, suggesting that the
ATG10rs3734114C/C variant could be a risk factor for AML.
Finally, in our study, we did not find any association between the ATG10rs1864183 and
AML. Nevertheless, its association with the development of pharyngeal cancer has been
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previously described [50]. Altogether, our results show the potential application of the
ATG10rs1864182 and ATG10rs3734114 as risk biomarkers for AML.
Random association between ATG10rs1864182 and ATG10rs3734114 was observed when
analyzing the LD between the two alleles. This indicates that the SNPs are not mutually
exclusive, even though they have opposite association with AML. Because of the low
probability of ATG10rs3734114, we do not have enough subjects to evaluate which effect
(protective or risk) prevails in case of co-occurrence, but it would be interesting to address
this in the future. It would also be interesting to explore association between these two
SNPs and other described SNPs impacting AML [19].
After flagging the association of ATG10rs1864182G and ATG10rs3734114C/C with AML,
we explored which potential impact those sequence variations might have on mRNA
expression and protein function in healthy individuals. Although we were able to detect
alterations in the ATG10 protein, with decreased levels of the long isoform in the presence
of ATG10rs1864182G, the amount of ATG10 transcripts was not altered. It is important
to note that the primers used in our study amplify all the isoforms and do not allow a
selective quantification of the different ATG10 transcripts. A putative differential expression
between transcripts could justify why ATG10rs1864182 is described to act as an expression
quantitative trait locus across multiple tissues, including whole blood, in the Genotype-
Tissue Expression (GTEx) project [51].
The decreased protein levels of ATG10 long isoform in ATG10rs1864182G carriers were
associated with the reduction of autophagic flux, its canonical function, in agreement with
previous observations [21]. Given the role of autophagy in leukemia [52], and in chemother-
apy susceptibility and resistance [53–55], this reduction in autophagy could potentially be
beneficial to lower the probability of developing AML. In the ATG10 immunoblot profile
(Supplementary Figure S2), we detected bands with a similar molecular weight as ATG10
isoforms. Although not described in literature, we hypothesize that these other detected
bands could correspond to yet unknown ATG10 isoforms or even ATG10 isoforms that
underwent post-translational modifications, which may alter their mobility in the SDS-Page
gel. This hypothesis should be explored further in future studies.
Regarding ATG10rs3734114C/C, due to the low number of individuals in the cohort, no
conclusions can be drawn with respect to mRNA levels, protein levels and autophagy. For
this reason, an increased number of homozygous mutants for ATG10rs3734114 are needed,
or alternatively an in vitro approach using gene editing could be adopted.
As with ATG10rs1864182, the ATG10rs3734114 is characterized by a missense mutation
resulting in a codon for a different amino acid. These mutations can potentially change the
functional role of ATG10 in autophagy and/or in other non-canonical processes in which it
may be involved. Hopefully, with advances in artificial intelligence tools uncovering the
3D shapes of proteins such as AlphaFold [56], accurate predictions of protein structural
changes due to SNPs will enable a better understanding of the biological implications of
these mutations. Future studies should also aim to understand if any of the ATG10 isoforms
is involved in non-canonical roles [57] affecting the likelihood of AML.
5. Conclusions
In conclusion, we found an association between ATG10rs1864182G and a lower-risk of
developing AML, which is accompanied by an impairment of ATG10’s autophagy function.
In addition, we describe an increased risk of developing AML in individuals carrying
the ATG10rs3734114C/C. Our work reveals new mechanisms by which genetic variations in
ATG10 may coordinate the development of AML. The gathered evidence could be further
exploited in prevention strategies or screening protocols of subjects carrying other risk
factors for AML, such as CHIP individuals.
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the blot represented in Figure 2A and 2H. Figure S4. The whole Western blot showing all bands and
molecular weight markers of the blot represented in Figure 2O. Table S1: Association of autophagy
SNPs with Acute Myeloid Leukemia (AML); Table S2: Primer sets used to perform the qPCR to
evaluate ATG10 expression (housekeepers: GAPDH, RPL13A and B2M).
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